» Articles » PMID: 22419386

Structured Histopathology Profiling of Chronic Rhinosinusitis in Routine Practice

Overview
Date 2012 Mar 16
PMID 22419386
Citations 58
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Tissue eosinophilia in chronic rhinosinusitis (CRS) is a marker of inflammatory disorders recalcitrant to surgical intervention. Eosinophilic chronic rhinosinusitis (ECRS) is traditionally associated with asthma, polyps, aspirin sensitivity, high serum eosinophilia, and elevated immunoglobulin E (IgE). However, patients with ECRS may not present with these associations and there is a need to establish other surrogate markers. The objective of the study was to determine the associations between the histopathology, serology, and clinical characteristics in CRS patients.

Methods: A cross-sectional study was undertaken of CRS patients undergoing surgery. Tissue eosinophilia and other pathological features were compared to traditional surrogate features of ECRS, as well as to symptoms, and to radiologic and endoscopic scores.

Results: A total of 51 patients were assessed (47% female, mean age 46.6 ± 4.1 years). High tissue eosinophilia (>10 per high-power field [HPF]) was more prominent in polyps (84%) (χ(2) = 25.76; p < 0.01) but was also seen in nonpolyp patients (19%). Asthma was not associated with high tissue eosinophilia (p = 0.60), with 43% of nonasthmatics demonstrating high tissue eosinophilia. Serum eosinophilia predicted high tissue eosinophilia at >0.30 × 10(9)/L or 4.4% of leukocytes (sensitivity 52%, specificity 87%, receiver operating characteristic [ROC] p = 0.001), with low negative predictive value. Serum IgE was nonpredictive (p = 0.08).

Conclusion: The diagnosis of ECRS has unique prognostic implications. Traditional features of the ECRS phenotype are not necessarily reliable markers for the presence of tissue eosinophilia. Serum eosinophilia may be a good surrogate marker of tissue eosinophilia but of limited use. The routine use of structured histopathology reporting in CRS is suggested, to allow for the diagnosis of ECRS and to identify other prognostic markers.

Citing Articles

Histopathology of Chronic Rhinosinusitis and Sinonasal Inflammatory Polyps.

Mansour M, Hernandez-Prera J Head Neck Pathol. 2025; 19(1):35.

PMID: 40088323 DOI: 10.1007/s12105-025-01760-8.


Chronic rhinosinusitis with nasal polyps: Key considerations in the multidisciplinary team approach.

Pfaar O, Peters A, Taille C, Teeling T, Silver J, Chan R Clin Transl Allergy. 2025; 15(1):e70010.

PMID: 39794887 PMC: 11723824. DOI: 10.1002/clt2.70010.


Nonsteroidal antiinflammatory drug-exacerbated respiratory disease: molecular mechanism, management and treatment.

Ley-Tomas J, Xicotencatl-Tellez A, Garcia-Cruz M, Jimenez-Chobillon M Front Allergy. 2024; 5:1462985.

PMID: 39665076 PMC: 11631927. DOI: 10.3389/falgy.2024.1462985.


Significance as a Prognostic Factor of Eosinophil Count in Nasal Polyp Tissue in Patients with Chronic Rhinosinusitis Accompanied by Asthma.

Kim M, Cho S, Lee H, Jung S, Jeong J J Clin Med. 2024; 13(19).

PMID: 39407908 PMC: 11477001. DOI: 10.3390/jcm13195849.


When the Nose Meets the Lab: Histopathological Analysis in Chronic Rhinosinusitis with Nasal Polyps for Routine Clinical Practice.

Alobid I, Armengot-Carceller M, Pinilla Urraca M, Maza-Solano J, Gonzalez Guijarro I, Umbria Jimenez S Curr Allergy Asthma Rep. 2024; 24(12):657-665.

PMID: 39373848 PMC: 11485015. DOI: 10.1007/s11882-024-01180-8.